19
Participants
Start Date
March 3, 2022
Primary Completion Date
June 19, 2024
Study Completion Date
June 19, 2024
OTR4132MD
"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
CHU Bordeaux Pellegrin, Bordeaux
CHU Grenoble Alpes, Grenoble
CHU Nancy, Nancy
Collaborators (1)
European Commission
OTHER
Euraxi Pharma
INDUSTRY
Organ, Tissue, Regeneration, Repair and Replacement
INDUSTRY